Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), [3] [4] [5] which has no cure.

2019年11月21日 · Emapalumab is the first cytokine-targeting therapy approved specifically for the treatment of HLH. This treatment involves the infusion of a monoclonal antibody targeting IFN-γ along with dexamethasone, and resulted in a high overall response rate in a small pediatric population of patients with primary HLH.

2020年5月6日 · Emapalumab is a fully human IgG1 anti–interferon-γ monoclonal antibody that binds free and receptor-bound interferon-γ (inhibiting receptor dimerization and transduction of interferon-γ...

On November 20, 2018, the Food and Drug Administration approved emapalumab (GAMIFANT, Novimmune SA), a monoclonal antibody that binds and neutralizes interferon gamma, for adult and pediatric...

Emapalumab is a fully human immunoglobulin G 1 monoclonal antibody that noncompetitively inhibits IFN-γ. It binds with high affinity ( K d = 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. 10

2024年7月22日 · What is emapalumab? Emapalumab is used together with a medicine called dexamethasone to treat hemophagocytic lymphohistiocytosis (HLH), a rare disease that is sometimes inherited. HLH causes your immune system to attack healthy blood cells, which can lead to serious or life-threatening side effects on your spleen or liver.

2023年8月21日 · Emapalumab is a prescription medication indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or …

2023年11月2日 · Emapalumab, a fully human immunoglobulin G1 anti-interferon-γ (IFNγ) monoclonal antibody, binds free and receptor-bound IFNγ, neutralizing its biologic activity.

Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-γ (IFN-γ), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH).

Emapalumab-lzsg injection is used to treat a blood disorder called primary hemophagocytic lymphohistiocytosis (HLH) that is hard to treat (refractory), recurrent, or has worsened (progressive), or when other treatments that have been used did not work well.